15 hrs ago
VIVUS Announces License and Commercialization Agreement With Sanofi...
VIVUS, Inc. today announced that it has entered into a License and Commercialization Agreement with Sanofi to commercialize avanafil on an exclusive basis in Africa, the Middle East, Turkey, and the Commonwealth of Independent States including Russia.
Tue Dec 10, 2013
Orexigen Completes Financing Deal
Orexigen announced details of a $115 million financing deal Monday. The financing consists of $115 million in coverable notes due 2020.
Thu Dec 05, 2013
Small Cap Stocks in a Bear Hug - Alpha Natural Resources,...
StockRunway.com issues special report on - Alpha Natural Resources, Inc. , VIVUS, Inc. , Molycorp Inc , AVG Technologies NV Alpha Natural Resources, Inc. stock is at $6.73, down -2.75 percent from its previous close of $6.92.
Tue Dec 03, 2013
Vivus Needs Catalyst For Qsymia
Vivus is the company responsible for the anti-obesity drug Qsymia. The company is marketing the drug on its own and of late sales have been pretty flat.
Mon Dec 02, 2013
Orexigen Announces $100 Million Offering
On the heels of some very positive news regarding a cardiovascular study last week, Orexigen Therapeutics has now announced a proposed $100 million Senior Convertible Note offering .
Fri Nov 29, 2013
Orexigen: Caution, Profit Taking And Money Making
The shares of Orexigen are up approximately 17% since November 25, after the company released positive interim data for the Light study.
Tue Nov 26, 2013
The Motley Fool
The Good News, Bad News for Belviq: a Now the Good News
Belviq, Arena Pharmaceuticals ' lead obesity drug, continues to rack up mediocre sales numbers as sales performance continues to lag expectations.
Mon Nov 25, 2013
UPDATE 1-Orexigen diet drug does not increase heart risks; shares rise
Orexigen Therapeutics Inc said study data showed its experimental obesity drug did not increase heart-related risks, sending its shares up 28 percent in premarket trading.
Thu Nov 21, 2013
Vivus Supports New Obesity Guidelines
VIVUS, Inc. , today announced its support of new clinical practice guidelines urging healthcare providers to take an active role in helping overweight or obese patients achieve and maintain a healthy body weight.
Mon Nov 18, 2013
Research Alert-Vivus: Roth cuts target price
VIVUS Inc : * Roth cuts target price to $12 from $14; rating neutral For a summary of rating and price target changes on U.S. companies: Reuters Eikon users, click on Reuters 3000Xtra users, double-click Thomson ONE users, type in RT/RCH/US For a summary of rating and price target changes on Canadian companies: Reuters Eikon users, click on Reuters ... (more)
RDInvesting Provides Investors with Free In-Depth Equity Reports on...
Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events.
Will Orexigen Make A 70%+ Upside Move Soon?
Obesity drug stocks have been hot ticket items in the biopharma world ever since Arena Pharmaceuticals and Vivus got their respective anti-obesity meds approved by the FDA.
Sat Nov 16, 2013
WallachBeth Capital Initiates Coverage on VIVUS
The firm set a "hold" rating and a $11.00 price target on the stock. WallachBeth Capital's target price suggests a potential upside of 11.79% from the stock's previous close.
Fri Nov 15, 2013
Annaly Capital, VIVUS And Others Insiders Have Been Buying
Insiders may sell shares for any number of reasons, but conventional wisdom says that insiders really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.
Eminence Capital to propose removal of directors from Men's Wearhouse
JoS. A. Bank says would consider new proposal if Men's Wearhouse changes stance In response to inquiries with respect to the actions Eminence Capital has taken regarding The Men's Wearhouse , Jos.
Wed Nov 13, 2013
VIVUS Announces Issuance of Two Key U.S. Patents for Qsymia; Patent...
VIVUS,Inc. , a biopharmaceutical company commercializing Qsymia capsules CIV for the treatment of obesity, today announced that the United States Patent and Trademark Office has issued U.S. Patent Nos.